Nalaganje...

Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD

BACKGROUND: When faced with uncertainties about the effects of medical interventions regulatory agencies, guideline developers, clinicians, and researchers commonly ask for more research, and in particular for more randomized trials. The conduct of additional randomized trials is, however, sometimes...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMC Med
Main Authors: Puhan, Milo A., Yu, Tsung, Boyd, Cynthia M., ter Riet, Gerben
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2015
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4490602/
https://ncbi.nlm.nih.gov/pubmed/26137986
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-015-0398-0
Oznake: Označite
Brez oznak, prvi označite!